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Abstract
Introduction: Peripheral primitive neuroectodermal tumor of the cervix uteri is extremely rare. Between 1987 and
2010, there were only nine cases reported in the English literature, with considerably different management
policies.
Case presentation: A 45-year-old Iranian woman presented to our facility with a primitive neuroectodermal tumor
of the cervix uteri. Her clinical stage IB2 tumor was treated successfully with chemotherapy. Our patient underwent
radical hysterectomy. There was no trace of the tumor after four years of follow-up.
Conclusions: According to current knowledge, primitive neuroectodermal tumors belong to the Ewing’s sarcoma
family, and the improvement of treatment outcome in our patient was due to dose-intensive neoadjuvant
chemotherapy, surgery and consolidation chemotherapy in accordance with the protocol for bony Ewing’s
sarcoma.
Introduction
Peripheral primitive neuroectodermal tumor (PNET) of
the cervix is extremely rare, and to the best of our
knowledge between 1987 and 2010 only nine cases were
described in the English literature [1-8]. The protocol
for treatment in these previous cases varied consider-
ably, partly due to the rarity of the disease and partly
due to the different time periods of diagnosis and
treatment.
Case presentation
A 45-year-old Iranian woman presented to our Univer-
sity Hospital with a PNET of the cervix. After clinical
staging and discussion at our Gynecology Oncology
Multidisciplinary Team (GOMDT) meeting, treatment
began.
Our patient was multiparous and had initially pre-
sented to a local regional facility with yellow purulent
vaginal discharge for the last three months. Upon exam-
ination by a gynecologist, a biopsy was taken from a
bulging cervical tumor, and a diagnosis of a small round
cell malignant tumor was made based on analysis of the
sample. Our patient was then referred to our center.
Bimanual pelvic examination under general anesthesia
revealed a 4 × 5 cm mass apparently arising from the
anterior lip of the cervix, producing yellow vaginal dis-
charge; the size of the uterus was around the size of a
10 week pregnancy. There was no extension of the
lesion into the vagina, parametria, or adjacent organs
including the bladder and rectum. The tumor was clini-
cally at stage IB2. A repeat cervical biopsy was taken for
confirmation of the tumor type, which was prepared
and analyzed by an expert cytopathologist using immu-
nohistochemistry (IHC).
The slides of the biopsy taken in the regional hospital
were revised, and additional tumor material from the
second biopsy taken in our institute was examined. Both
biopsies showed the same histological appearances:
small blue-staining tumor cells with little cytoplasm
lying closely packed in sheets without rosette or gland
formation. The cytoplasm of the tumor cells was clearly
shown to contain glycogen on staining with periodic
acid-Schiff (PAS). Immunohistochemistry stains for a
number of epithelial markers were negative including
CD3, terminal deoxynucleotidyl transferase (TdT), des-
min, latent class analysis (LCA), neurofilament, CD10,
CD20, cytokeratin, and carcinoembryonic antigen
(CEA). However CD99, chromogranin, and synaptophy-
sin showed strong positivity and neuron-specific enolase
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ings, a diagnosis of PNET of the cervix was made.
Laboratory examination results from hematology, elec-
trolyte, liver and renal function tests were normal. Spiral
computerized tomography (CT) scanning of the chest
and abdomen showed multiple para-aortic adenopathies
(20 mm in diameter). The results of rectosigmoidoscopy,
as well as a whole body scan, were normal. There were
no signs of lung or liver metastasis.
A f t e rd i s c u s s i o ni no u rG O M D Tm e e t i n g ,i tw a s
decided to treat our patient in the following manner: (1)
Initially, our patient would received a neoadjuvant che-
motherapy regimen consisting of vincristine 2 g, adria-
mycin 75 mg/m
2, cyclophosphamide 1200 mg/m
2 (VAC)
alternating with ifosfamide 1800 mg/m
2 plus etoposide
100 mg/m
2 during days 1 to 5; (2) then, surgical treat-
ment would be performed consisting of hysterectomy
and bilateral oophorectomy with or without lymphade-
nectomy depending on the findings at surgery; (3)
finally, chemotherapy or radiotherapy depending on the
findings at surgery and microscopic examination would
be started. A decision regarding consolidation therapy
would then ensue.
At the end of 12 weeks of chemotherapy, there was a
complete response of the primary tumor, and enlarged
para-aortic lymph nodes were revealed on CT scan. A
radical hysterectomy was therefore performed invol-
ving the uterus and bilateral ovaries along with the
proximal third of the vagina, and the bilateral parame-
trium, which were all removed. At the time of surgery
there were no enlarged pelvic or para-aortic lymph
nodes. As the para-aortic lymph nodes were not biop-
sied before chemotherapy due to our patient’sc o n d i -
tion, we decided to perform a complete para-aortic
and pelvic lymphadenectomy in addition to a radical
hysterectomy. Unfortunately, our patient’s general con-
dition prohibited a complete para-aortic and pelvic
lymphadenectomy, so only sampling of the pelvic
nodes was performed.
A macroscopic examination showed a tumor of 5 × 6
× 5 cm in the cervical location (Figure 1). Microscopic
examination of the removed tumor tissue showed a
small round cell tumor of the cervix with a depth of 8
mm to the stroma. In the histological examination of
uterus, vagina and parametrium no malignancy was
reported. No lymphovascular invasion was reported.
O n l yt h r e ep e l v i cn o d e sf r o mt h ep e l v i cl e f ts i d ea n d
right pelvic nodes were found along with the specimen,
which was negative for malignancy. All the pathology
reports were reviewed by another expert pathologist
(Figures 2,3,4,5).
After surgery, the same chemotherapy protocol was
continued for another 12 weeks. Finally, after comple-
tion of the treatment, chest and abdomen CT scans
consistently showed no enlargement of lymph nodes
and no sign of tumor.
Over more than four years of follow-up in our out-
patient clinic (every month for three months, then every
three months for the first year, then every six months to
date by the gynecologic oncologist and medical oncolo-
gist) there was no recurrence of the disease seen on
either physical examination or CT imaging.
Discussion
Our patient was diagnosed as having at least clinical
stage IB2 cervical cancer at the time of presentation.
From the results shown in Table 1, it seems that PNET
of the cervix can happen at any age. In a literature
review performed by Snijders-Keilholz et al.[ 9 ] ,t h e
range of age at diagnosis of the disease was between 21
and 60 years. PNET of the uterine cervix belongs to the
Ewing’s sarcoma family [10]. Although such tumors
usually occur in younger adults, often around the
Figure 1 Macroscopic view of the resected uterus.
Figure 2 Positive MIC2 (CD99) expression in the tumor cells.
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including the uterine cervix. Cytogenetic studies now
indicate that Ewing’s sarcoma and PNET have similar
histological features and should be considered as one
entity [10]. In our patient’s case, we did not have the
facilities to test for the t(11;22) translocation found in
Ewing/PNET. However, strong membranous staining
with CD99 was very characteristic and sensitive. Chro-
mogranin and synaptophysin test results were also posi-
tive. Furthermore, negative staining for a wide variety of
other markers including CD3, TdT, desmin, LCA, neu-
rofilament, CD10, CD20, cytokeratin, and CEA excluded
other types of small, blue, round cell tumor that entered
the differential diagnosis.
Ewing’s sarcoma must be considered as a systemic dis-
ease without adequate treatment in which more than
90% of patients die from secondary hematogenous
metastases, occurring mainly in the lung. Therefore, the
five-year survival rate can increase to 55% to 60% with
dose-intensive cytotoxic treatment regimens in localized
disease; the three-year disease-free survival rate was
reported to be 15% to 22% among patients with detect-
able metastases at time of diagnosis [11].
A ss h o w ni nT a b l e1 ,i ne a r lier reports the approach
to treatment of uterine cervix PNET was optimal local
surgical treatment followed by additional treatment such
as irradiation and/or chemotherapy. Recently however,
neoadjuvant chemotherapy followed by local treatment
has been favored because of improved results from the
addition of systemic therapy. Optimal management
must be based on a GOMDT decision. As all 10 cases
were at stage IB and mostly with no metastasis at the
time of diagnosis, it is assumed that a tumor in this
location produces symptoms at an early stage. Although,
as can be seen from Table 1, one patient as well as our
patient underwent chemotherapy first because the
tumor was too large to perform initial radical surgery,
the other cases had primary local treatment mainly con-
sisting of primary surgery (except in one patient which
was first treated with radiotherapy) followed by addi-
tional local radiotherapy or systemic treatment. Meta-
static disease developed after three years in one case,
and this patient died after a year.
It might be considered that neoadjuvant chemotherapy
is an overtreatment for the management of PNET. How-
ever, as Snijders-Keilholz et al. [9] mention, up to now
duration of follow-up of the reported cases is too short
(five to 42 months) to prove or reject this discussion. As
with Ewing’s sarcoma of other sites, we showed that
neoadjuvant chemotherapy in metastatic cases could
change an inoperable presentation to an operable state
for successful local and/or regional treatment.
Conclusions
Patients with localized PNET of the cervix should be
treated with dose-intensive neoadjuvant chemotherapy
Figure 3 Representative hematoxylin and eosin staining of the
tumor.
Figure 4 Positive synaptophysin stain in the tumor.
Figure 5 Tumor cells shown to be chromogranin A positive.
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after. Our patient was treated with a multimodal therapy
regime resulting in a disease-free state for at least four
years after diagnosis.
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